Волчаночный нефрит – современные аспекты диагностики и терапии. Часть I
https://doi.org/10.47360/1995-4484-2024-55-64
Аннотация
Волчаночный нефрит (ВН) по праву считается одним из наиболее частых среди тяжелых проявлений системной красной волчанки (СКВ); различные его клинические признаки встречаются не менее чем у 50% больных СКВ как в дебюте, так и на различных сроках болезни, а развитие ВН считается одним из наиболее важных предикторов смертности при СКВ. Среди различных его вариантов преобладает диффузный пролиферативный ВН с клинико-морфологическими признаками прогрессирования и быстрым развитием терминальной почечной недостаточности. Диагноз СКВ устанавливается на основании диагностических классификационных критериев Европейского альянса ревматологических ассоциаций/ Американской коллегии ревматологов (EULAR/ACR, European Alliance of Associations for Rheumatology/ American College of Rheumatology) 2019 г. Для подтверждения диагноза, оценки прогноза и выбора тактики лечения заболевания всем пациентам при отсутствии противопоказаний необходимо проведение биопсии почки. Помимо ВН, в спектр ассоциированных с СКВ вариантов поражения почек входят сосудистая патология, представленная тромботической микроангиопатией, волчаночной васкулопатией или васкулитом, тубулоинтерстициальное повреждение и волчаночная подоцитопатия.
При поддержке: Исследование проводилось в рамках научной темы FURS-2022-003.
Об авторах
С. К. Соловьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Соловьев Сергей Константинович
115522, Москва, Каширское шоссе, 34а
Н. Л. Козловская
ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Минздрава России
Россия
Россия
127473, Москва, ул. Делегатская, 20, стр. 1
Е. А. Асеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34а
А. А. Баранов
ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России
Россия
Россия
150000, Ярославль, ул. Революционная, 5
Н. Ю. Никишина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34а
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
115522, Москва, Каширское шоссе, 34а;
119991, Москва, ул. Трубецкая, 8, стр. 2
Список литературы
1. Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412
2. Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi: 10.14412/1995-4484-2020-5-14
3. Асеева ЕА, Лила АМ, Соловьев СК, Глухова СИ. Волчаночный нефрит как особый клинико-иммунологический фенотип системной красной волчанки. Современная ревматология. 2022;16(6):12-19. doi: 10.14412/1996-7012-2022-6-12-19
4. Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-262. doi: 10.1093/rheumatology/kev311
5. Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: A systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432-1441. doi: 10.1002/art.39594
6. Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010;62(6):873-880. doi: 10.1002/acr.20116
7. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009;36(1):63-67. doi: 10.3899/jrheum.080625
8. Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011-1020. doi: 10.1177/0961203320932219
9. Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65(8):2154-2160. doi: 10.1002/art.38006
10. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-2557. doi: 10.1002/art.21955
11. Maningding E, Dall’Era M, Trupin L, Murphy LB, Yazdany J. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: The California lupus surveillance project. Arthritis Care Res (Hoboken). 2020;72(5):622-629. doi: 10.1002/acr.23887
12. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159-168. doi: 10.1002/acr.20683
13. Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist’s perspective. Kidney Int. 2016;90(3):487-492. doi: 10.1016/j.kint.2016.03.042
14. Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis. 2011;70(2):393-394. doi: 10.1136/ard.2010.131482
15. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65(3):753-763. doi: 10.1002/art.37795
16. Lanata CM, Nititham J, Taylor KE, Chung SA, Torgerson DG, Seldin MF, et al. Genetic contributions to lupus nephritis in a multiethnic cohort of systemic lupus erythematous patients. PLoS One. 2018;13(6):e0199003. doi: 10.1371/journal.pone.0199003
17. Nee R, Martinez-Osorio J, Yuan CM, Little DJ, Watson MA, Agodoa L, et al. Survival disparity of African American versus non-African American patients with ESRD due to SLE. Am J Kidney Dis. 2015;66(4):630-637. doi: 10.1053/j.ajkd.2015.04.011
18. Korbet SM, Schwartz MM, Evans J, Lewis EJ; Collaborative Study Group. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244-254. doi: 10.1681/ASN.2006090992
19. McCarty GA, Harley JB, Reichlin M. A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum. 1993;36(11):1560-1565. doi: 10.1002/art.1780361110
20. Hiraki LT, Feldman CH, Liu J, Alarcón GS, Fischer MA, Winkelmayer WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669-2676. doi: 10.1002/art.34472
21. Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: Results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314-322. doi: 10.1177/0961203307087875
22. Yazdany J, Feldman CH, Liu J, Ward MM, Fischer MA, Costenbader KH. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken). 2014;66(4):617-624. doi: 10.1002/acr.22182
23. American College of Rheumatology Committee on Rheumatology Training and Workforce Issues; FitzGerald JD, Battistone M, Brown CR Jr, Cannella AC, Chakravarty E, et al. Regional distribution of adult rheumatologists. Arthritis Rheum. 2013;65(12):3017-3025. doi: 10.1002/art.38167
24. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089
25. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:1-276. doi: 10.1016/j.kint.2021.05.021
26. Ассоциация нефрологов, Научное общество нефрологов России, Общероссийская общественная организация нефрологов «Российское диализное общество». Клинические рекомендации. Диагностика и лечение волчаночного нефрита. М.;2021. URL: https://rusnephrology.org/wpcontent/uploads/2021/02/lupus.pdf
27. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Сlarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018; 93(4):789-796. doi: 10.1016/j.kint.2017.11.023
28. Насонова ВА. Системная красная волчанка. М.:Медицина;1972.
29. Тареева ИЕ. Волчаночный нефрит. М.:Медицина;1976.
30. Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7(1): 000389. doi: 10.1136/lupus-2020-000389
31. Wang H, Ren YL, Chang J, Gu L, Sun LY. A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol. 2017;33(1):17-25. doi: 10.5606/ArchRheumatol.2017.6127
32. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11): 1771-1782. doi: 10.1136/annrheumdis-2012-201940
33. Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: Look before you leap. Nephrol Dial Transplant. 2006;21:1749-1752. doi: 10.1093/ndt/gfl159
34. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819
35. Giannico G, Fogo AB. Lupus nephritis: Is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138-145. doi: 10.2215/CJN.03400412
36. Fogo AB. Approach to renal biopsy. Am J Kidney Dis. 2003;42(4): 826-836.
37. Anders HJ. Re-biopsy in lupus nephritis. Ann Transl Med. 2018;6(Suppl 1):41. doi: 10.21037/atm.2018.09.47
38. De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788-794. doi: 10.1016/j.kint.2018.05.021
39. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530. doi: 10.1111/j.1523-1755.2004.00443.x
40. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. doi: 10.2215/CJN.05780616
41. Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23:1298-1306. doi: 10.1093/ndt/gfm775
42. Haring CM, Rietveld A, van den Brand JA, Berden JHM. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol. 2012;23:149-154. doi: 10.1681/ASN.2011060558
43. Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al.; Conference Participants. Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):281-295. doi: 10.1016/j.kint.2018.11.008
44. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. doi: 10.1016/j.kint.2017.11.023
45. Duqun C, Hu W. Lupus podocytopathy: A distinct entity of lupus nephritis. J Nephrol. 2018;31(5):629-634. doi: 10.1007/s40620-017-0463-13
46. Makino H, Haramoto T, Shikata K, Ogura T, Ota Z. Minimalchange nephrotic syndrome associated with systemic lupus erythematosus. Am J Nephrol. 1995;15(5):439-441. doi: 10.1159/000168880
47. Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D’Agati VD. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. doi: 10.5414/cnp57120
48. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. doi: 10.1681/ASN.2004050350
49. Hertig A, Droz D, Lesavre P, Grünfeld JP, Rieu P. SLE and idiopathic nephrotic syndrome: Coincidence or not? Am J Kidney Dis. 2002;40(6):1179-1184. doi: 10.1053/ajkd.2002.36875
50. Wang YT, Chou HH, Chen FF, Chen MJ, Chiou YY. A case of minimal-change nephrotic syndrome in pediatric lupus erythematosus: Just a coincidence? Lupus. 2006;15(4):244-247. doi: 10.1191/0961203306lu2285cr
51. Bomback AS, Markowitz GS. Lupus podocytopathy: A distinct entity. Clini J Am Soc Nephrol: CJASN. 2016;11(4):547-548. doi: 10.2215/CJN.01880216
52. Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, et al. Clinicalmorphological features and outcomes of lupus podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. doi: 10.2215/CJN.06720615
53. Oliva-Damaso N, Payan J, Oliva-Damaso E, Pereda T, Bomback AS. Lupus podocytopathy: An overview. Adv Chronic Kidney Dis. 2019;26(5):369-375. doi: 10.1053/j.ackd.2019.08.011
54. Стариков ДВ, Козловская НЛ, Столяревич ЕС, Бондаренко ТВ, Волкова ОА. Особенности течения и трудности диагностики волчаночной подоцитопатии. Нефрология и диализ. 2022;24(4): 898-906. doi: 10.28996/2618-9801-2022-4-898-906
55. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654-666. doi: 10.1056/NEJMra1312353
56. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13:300-317. doi: 10.2215/CJN.00620117
57. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al.; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312-322. doi: 10.1111/jth.13571
58. Kotzen ES, Roy S, Jain K. Antiphospholipid syndrome nephropathy and other thrombotic microangiopathies among patients with systemic lupus erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-386. doi: 10.1053 /j.ackd. 2019.08.012
59. Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Renal Failure. 2020;42(1):19-29. doi: 10.1080/0886022X.2019.1702057
60. Barrera-Vargas A, Rosado-Canto R, Merayo-Chalico J, ArreolaGuerra JM, Mejía-Vilet JM, Correa-Rotter R, et al. Renal thrombotic microangiopathy in proliferative lupus nephritis: Risk factors and clinical outcomes: A case-control study. J Clin Rheumatol. 2016;22(5):235-240. doi: 10.1097/RHU.0000000000000425
61. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142
62. Bajema IG, Chuia JS, Bruijn JA. TMA: Tell me about it. J Rheumatol. 2019;46(11):1425-1427. doi: 10.3899/jrheum.190447
63. Anders HJ, Weening JJ. Kidney disease in lupus is not always “Lupus nephritis”. Arthritis Res Ther. 2013;15(2):108. doi: 10.1186/ar4166
64. Bridoux F, Vrtovsnik F, Noël C, Saunier P, Mougenot B, Lemaitre V, et al. Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant. 1998;13(2):298-304. doi: 10.1093/oxfordjournals.ndt.a027822
65. Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol. 2015;26(9):2239-2247. doi: 10.1681/ASN.2014050429
66. Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C, et al. Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol. 2019;46(11):1478-1484. doi: 10.3899/jrheum.180773
67. Bienaime F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int. 2017;91:34-44. doi: 10.1016/j.kint.2016.06.026
68. Tektonidou MG. Antiphospholipid syndrome nephropathy: From pathogenesis to treatment. Front Immunol. 2018;9:1181. doi: 10.3389/fimmu.2018.01181
69. Starck M, Abedinpour F, Dendorfer U, Wagner-Czekalla J, Pachmann M, Mann JF, et al. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression – Report of two cases. Eur J Haematol. 2005;75(5):436-440. doi: 10.1111/j.1600-0609.2005.00526.x
70. George JN, Vesely SK, James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007;100(5)512-514. doi: 10.1097/SMJ.0b013e318046583f
71. Mejia-Vilet JM, Gómez-Ruiz IA, Cruz C, Méndez-Pérez RA, Comunidad-Bonilla RA, Uribe-Uribe NO, et al. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis. Clin Rheumatol. 2021;40(6):2233-2242. doi: 10.1007/s10067-020-05499-1
72. Насонов ЕЛ, Решетняк ТМ, Алекберова ЗС. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020;92(5):4-14. doi: 10.26442/00403660.2020.05.000697
73. Kello N, El Khoury L, Marder G. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49:74-83. doi: 10.1016/j.semarthrit.2018.11.005
74. Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopa-thy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-2094. doi: 10.1182/bloodadvances.2018019596
75. Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore). 2014;93(26):e143. doi: 10.1097/MD.0000000000000143
76. López-Benjume B, Rodríguez-Pintó I, Amigo MC, Erkan D, Shoenfeld Y, Cervera R, et al.; on behalf the CAPS Registry Project Group/European Forum on Antiphospholipid Antibodies. Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the “CAPS Registry”. Autoimmun Rev. 2022;21(4):103055. doi: 10.1016/j.autrev.2022.103055
77. Zhang B, Xing G. Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation. Front Immunol. 2022;13:1081942. doi: 10.3389/fimmu.2022.1081942
78. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50(8):2569-2579. doi: 10.1002/art.20433
79. Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715-723. doi: 10.1038/ki.2012.409
80. Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023 May;23(5):274-288. doi: 10.1038/s41577-022-00787-0
81. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9
82. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: Core curriculum 2020. Am J Kidney Dis. 2020;76(2):265-281. doi: 10.1053/j.ajkd.2019.10.017
83. Цанян МЭ, Александрова ЕН, Соловьев СК, Насонов ЕЛ. Антитела к C1q при системной красной волчанке – биологический маркер активности, предиктор развития нефрита и неблагоприятного жизненного прогноза. Научно-практическая ревматология. 2013;51(1):71–75.
84. Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;55(4):452-461. doi: 10.14412/1995-4484-2019-452-461
85. Obrișcă B, Sorohan B, Tuță L, Ismail G. Advances in lupus nephritis pathogenesis: From bench to bedside. Int J Mol Sci. 2021;22(7):3766. doi: 10.3390/ijms22073766
86. Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383
87. Панафидина ТА, Сохова МА, Попкова ТВ Черкасова МВ, Новиков АА, Александрова ЕН, и др. Клиническое значение концентраций лигандов BAFF и APRIL при системной красной волчанке. Научно-практическая ревматология. 2016;54(2):145-154. doi: 10.14412/1995-4484-2016-145-15
88. Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: New progress in diagnosis and treatment. J Autoimmun. 2022;132:102871. doi: 10.1016/j.jaut.2022.102871
89. Bhargava R, Li H, Tsokos GC. Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Curr Opin Rheumatol. 2023;35(2):107-116. doi: 10.1097/BOR.0000000000000887
90. Paquissi FC, Abensur H. The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Front Med (Lausanne). 2021;8:654912. doi: 10.3389/fmed.2021.654912
91. Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021;33(2):197-204. doi: 10.1097/BOR.0000000000000777
92. Robson KJ, Kitching AR. Tertiary lymphoid tissue in kidneys: Understanding local immunity and inflammation. Kidney Int. 2020;98(2):280-283. doi: 10.1016/j.kint.2020.04.026
93. Kinloch AJ, Chang A, Ko K, Henry Dunand CJ, Henderson S, Maienschein-Cline M, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 2014;66(12):3359-3370. doi: 10.1002/art.38888
94. Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi: 10.2215/CJN.01070118
95. Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol. 2017 Dec;185:95-99. doi: 10.1016/j.clim.2016.04.010
96. Zhao Y, Wei W, Liu ML. Extracellular vesicles and lupus nephritis – New insights into pathophysiology and clinical implications. J Autoimmun. 2020 Dec;115:102540. doi: 10.1016/j.jaut.2020.102540
97. Momtaz M, Fayed A, Wadie M, Gamal SM, Ghoniem SA, Sobhy N, et al. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: A university hospital experience. Lupus. 2017;26(14): 1564-1570. doi: 10.1177/0961203317716320
98. Tang Y, Qin W, Peng W, Tao Y. Development and validation of a prediction score system in lupus nephritis. Medicine (Baltimore). 2017;96(37):8024. doi: 10.1097/MD.0000000000008024
99. Park DJ, Kang JH, Lee JW, Lee KE, Kim TJ, Park YW, et al. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus. 2017;26(11):1139-1148. doi: 10.1177/0961203317694257
100. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European
101. Chen S, Tang Z, Zhang Y, Liu Z, Zhang H, Hu W, et al. Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol. 2013;38(6):445-452. doi: 10.1159/000356184
102. Kammoun K, Jarraya F, Bouhamed L, Kharrat M, Makni S, Hmida MB, et al. Poor prognostic factors of lupus nephritis. Saudi J Kidney Dis Transpl. 2011;22(4):727-732.
103. Rekvig OP. SLE classification criteria: Is «The causality principle» integrated and operative - and do the molecular and genetical network, on which criteria depend on, support the definition of SLE as «a one disease entity» – A theoretical discussion. Autoimmun Rev. 2023;22(12):103470. doi: 10.1016/j.autrev.2023.103470
104. Broder A, Mowrey WB, Khan HN, Jovanovic B, Londono-Jimenez A, Izmirly P, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Semin Arthritis Rheum. 2018;47(4):545-551. doi: 10.1016/j.semarthrit.2017.07.007
105. Wilson PC, Kashgarian M, Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney J. 2018;11:207-218. doi: 10.1093/ckj/sfx093
106. Sciascia S, Cozzi M, Barinotti A, Radin M, Cecchi I, Fenoglio R, et al. Renal fibrosis in lupus nephritis. Int J Mol Sci. 2022;23(22):14317. doi: 10.3390/ijms232214317
107. Yung S, Chan TM. Molecular and immunological basis of tubulo-interstitial injury in lupus nephritis: A comprehensive review. Clin Rev Allergy Immunol. 2017 Apr;52(2):149-163. doi: 10.1007/s12016-016-8533-z
108. Rijnink EC, Teng YKO, Wilhelmus S, Almekinders M, Wolterbeek R, Cransberg K, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-743. doi: 10.2215/CJN.10601016
109. Hernandez-Molina G, García-Trejo LP, Uribe N, Cabral AR. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without an tiphospholipid syndrome. Clin Exp Rheumatol. 2015;33(4):503-508.
110. Mejía-Vilet JM, Córdova-Sánchez BM, Uribe-Uribe NO, Correa-Rotter R, Morales-Buenrostro LE. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus. 2017;26(10): 1042-1050. doi: 10.1177/0961203317692419
111. Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C, et al. Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol. 2019;46(11):1478-1484. doi: 10.3899/jrheum.180773
112. Silvariño R, Sant F, Espinosa G, Pons-Estel G, Solé M, Cervera R, et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011;20(7):721-729. doi: 10.1177/0961203310397410
Рецензия
Для цитирования:
Соловьев С.К., Козловская Н.Л., Асеева Е.А., Баранов А.А., Никишина Н.Ю., Насонов Е.Л. Волчаночный нефрит – современные аспекты диагностики и терапии. Часть I. Научно-практическая ревматология. 2024;62(1):55-64. https://doi.org/10.47360/1995-4484-2024-55-64
For citation:
Solovyev S.K., Kozlovskaya N.L., Aseeva E.A., Baranov A.A., Nikishina N.Yu., Nasonov E.L. Lupus nephritis – modern aspects of diagnosis and therapy. Part I. Rheumatology Science and Practice. 2024;62(1):55-64. (In Russ.) https://doi.org/10.47360/1995-4484-2024-55-64
Просмотров:
798
Послать статью по эл. почте 